| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $...
 
																	D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
 
																	Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted rad...
 
																	Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and raises the price target from ...
 
																	
 
																	Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...
 
																	Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...
 
																	U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Thursday. The Dow traded ...
 
																	Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outst...